Answers are grounded in this paper and cite their sources.
Reliable biomarkers for cancer early detection, prognostic stratification, recurrence surveillance, and treatment-response prediction remain clinically insufficient. tRNA-derived small RNAs (tsRNAs) are abundant, structurally compact, and recurrently dysregulated in malignancy, and have been widely proposed as liquid-biopsy analytes. Their biogenesis, mechanisms, and therapeutic prospects have been reviewed extensively. What has not been assessed is whether the reported clinical evidence supports the claims attached to it, and that is the question this review addresses. We appraise published circulating tsRNA studies against four criteria that govern progression toward clinical use: analytical validity, cohort design and comparator choice, independent validation, and demonstrated incremental clinical utility. Biology is summarized only where it bears on measurement-the distinct enzymatic routes that generate tRNA-derived fragments and tRNA halves, the terminal chemistries they impose, the modifications that bias library construction, and the extracellular biology that determines what is actually quantified in blood. Candidates are then re-classified by intended use and graded by validation level in a structured evidence table reporting cohort size, comparator group, platform, normalization, diagnostic performance, and validation status. Most candidates rest on single-center retrospective case-control comparisons against healthy donors. Detection in stage I disease has been conflated with early detection, and postoperative decline with rcrrence monitoring. Disease specificity is frequently untested, notably for glycine-GCC-derived fragments, which also rise in active inflammatory bowel disease. No circulating tsRNA has yet demonstrated incremental clinical value in a prospectively validated setting. tsRNAs remain a biologically compelling and analytically tractable biomarker reservoir. Realizing that potential will require standardized pre-analytics, clinically relevant comparators, transfer to analytically validated targeted assays, and independent multicenter validation. We provide a minimum reporting checklist and a nomenclature cross-walk to support this.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: